The only clinical application is Telomelysin (OBP-301), a TERT-driven oncolytic adenovirus that specifically introduces the TERT promoter into tumor cells, which is being investigated in a phase I trial in HCC.446 In this study, the therapeutic efficacy of OBP-301 was less than that of other second-line systemic targeted therapies. This evidence concerns the gene TERT and neoplasm.